PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C
First Claim
1. A method of treating a host infected with a flavivirus or pestivirus, comprising administering an effective amount of an anti-pestivirus or anti-flavivirus biologically active ribofuranonucleoside of Formula (I):
- or a pharmacologically acceptable salt or prodrug thereof, wherein;
R is H, mono-, di-, or triphosphate, a stabilized phosphate, or phosphonate;
X is O, S[O]n, CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—
O-alkyl, CH—
O-alkenyl, CH—
O-alkynyl, CH—
S-alkyl, CH—
S-alkenyl, CH—
S-alkynyl, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, SCH-halogen, or C-(halogen)2, wherein alkyl, alkenyl or alkynyl may optionally be substituted;
n is 0-2;
such than when X is CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—
O-alkyl, CH—
O-alkenyl, CH—
O-alkynyl, CH—
S-alkyl, CH—
S-alkenyl, CH—
S-alkynyl, CH-halogen, or C-(halogen)2,then each R1 and R1′
is independently H, OH, optionally substituted alkyl, lower alkyl, azido, cyano, optionally substituted alkenyl or alkynyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), —
O(alkynyl), halogen, halogenated alkyl, —
NO2, —
NH2, —
NH(lower alkyl), —
N(lower alkyl)2, —
NH(acyl), —
N(acyl)2, —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, SCH-halogen, wherein alkyl, alkenyl, and/or alkynyl may optionally be substituted; and
such that when X is O, S[O]n, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, or SCH-halogen,then each R1 and R1′
is independently H, optionally substituted alkyl, lower alkyl, azido, cyano, optionally substituted alkenyl or alkynyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), halogenated alkyl, —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, —
C(H)═
N—
NH2, C(S)NH2, C(S)NH(alkyl), or C(S)N(alkyl)2, wherein alkyl, alkenyl and/or alkynyl may optionally be substituted;
each R2 and R3 independently is OH, NH2, SH, F, Cl, Br, I, CN, NO2, —
C(O)NH2, —
C(O)NH(alkyl), and —
C(O)N(alkyl)2, N3, optionally substituted alkyl, lower alkyl, optionally substituted alkenyl or alkynyl, halogenated alkyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), —
O(acyl), —
O(alkyl), —
O(alkenyl), —
O(alkynyl), —
OC(O)NH2, NC, C(O)OH, SCN, OCN, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), an amino acid residue or derivative, a prodrug or leaving group that provides OH in vivo, or an optionally substituted 3-7 membered heterocyclic ring having O, S and/or N independently as a heteroatom taken alone or in combination;
each R2′
and R3′
independently is H;
optionally substituted alkyl, alkenyl, or alkynyl;
—
C(O)O(alkyl), —
C(O)O(lower alkyl), —
C(O)O(alkenyl), —
C(O)O(alkynyl), —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), halogen, halogenated alkyl and particularly CF3, azido, cyano, NO2, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), NH2, —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), —
NH(acyl), or —
N(acyl)2, and R3 at 3′
-C may also be OH; and
Base is selected from the group consisting of;
whereineach R′ and
R″
independently is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, halogenated alkyl, OH, CN, N3, carboxy, C1-4alkoxycarbonyl, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfonyl, (C1-4 alkyl)0-2 aminomethyl;
each W is Cl, Br, I, F, halogenated alkyl, alkoxy, OH, SH, O-alkyl, S-alkyl, O-alkenyl, O-alkynyl, S-alkenyl, S-alkynyl, —
OC(O)NR4R4, O-acyl, S-acyl, CN, SCN, OCN, NO2, N3, NH2, NH(alkyl), N(alkyl)2, NH-cycloalkyl, NH-acyl, NH═
NH, CONH2, CONH(alkyl), or CON(alkyl)2; and
each R4 is independently H, acyl, or C1-6 alkyl;
each Z is O, S, NH, N—
OH, N—
NH2, NH(alkyl), N(alkyl)2, N-cycloalkyl, alkoxy, CN, SCN, OCN, SH, NO2, NH2, N3, NH═
NH, NH(alkyl), N(alkyl)2, CONH2, CONH(alkyl), or CON(alkyl)2;
with the caveat that when X is S, then the compound is not 5-(4-amino-imidazo[4,5-d][1,2,3]triazin-7-yl)-2-hydroxymethyl-tetrahydro-thiophen-3-ol or 7-(4-hydroxy-5-hydroxy-methyl-tetrahydro-thiophen-2-yl)-3,7-dihydro-imidazo[4,5-d][1,2,3]triazin-4-one.
1 Assignment
0 Petitions
Accused Products
Abstract
This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.
77 Citations
67 Claims
-
1. A method of treating a host infected with a flavivirus or pestivirus, comprising administering an effective amount of an anti-pestivirus or anti-flavivirus biologically active ribofuranonucleoside of Formula (I):
-
or a pharmacologically acceptable salt or prodrug thereof, wherein; R is H, mono-, di-, or triphosphate, a stabilized phosphate, or phosphonate; X is O, S[O]n, CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—
O-alkyl, CH—
O-alkenyl, CH—
O-alkynyl, CH—
S-alkyl, CH—
S-alkenyl, CH—
S-alkynyl, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, SCH-halogen, or C-(halogen)2, wherein alkyl, alkenyl or alkynyl may optionally be substituted;n is 0-2; such than when X is CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—
O-alkyl, CH—
O-alkenyl, CH—
O-alkynyl, CH—
S-alkyl, CH—
S-alkenyl, CH—
S-alkynyl, CH-halogen, or C-(halogen)2,then each R1 and R1′
is independently H, OH, optionally substituted alkyl, lower alkyl, azido, cyano, optionally substituted alkenyl or alkynyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), —
O(alkynyl), halogen, halogenated alkyl, —
NO2, —
NH2, —
NH(lower alkyl), —
N(lower alkyl)2, —
NH(acyl), —
N(acyl)2, —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, SCH-halogen, wherein alkyl, alkenyl, and/or alkynyl may optionally be substituted; andsuch that when X is O, S[O]n, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, or SCH-halogen, then each R1 and R1′
is independently H, optionally substituted alkyl, lower alkyl, azido, cyano, optionally substituted alkenyl or alkynyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), halogenated alkyl, —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, —
C(H)═
N—
NH2, C(S)NH2, C(S)NH(alkyl), or C(S)N(alkyl)2, wherein alkyl, alkenyl and/or alkynyl may optionally be substituted;each R2 and R3 independently is OH, NH2, SH, F, Cl, Br, I, CN, NO2, —
C(O)NH2, —
C(O)NH(alkyl), and —
C(O)N(alkyl)2, N3, optionally substituted alkyl, lower alkyl, optionally substituted alkenyl or alkynyl, halogenated alkyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), —
O(acyl), —
O(alkyl), —
O(alkenyl), —
O(alkynyl), —
OC(O)NH2, NC, C(O)OH, SCN, OCN, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), an amino acid residue or derivative, a prodrug or leaving group that provides OH in vivo, or an optionally substituted 3-7 membered heterocyclic ring having O, S and/or N independently as a heteroatom taken alone or in combination;each R2′
and R3′
independently is H;
optionally substituted alkyl, alkenyl, or alkynyl;
—
C(O)O(alkyl), —
C(O)O(lower alkyl), —
C(O)O(alkenyl), —
C(O)O(alkynyl), —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), halogen, halogenated alkyl and particularly CF3, azido, cyano, NO2, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), NH2, —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), —
NH(acyl), or —
N(acyl)2, and R3 at 3′
-C may also be OH; andBase is selected from the group consisting of; wherein each R′ and
R″
independently is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, halogenated alkyl, OH, CN, N3, carboxy, C1-4alkoxycarbonyl, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfonyl, (C1-4 alkyl)0-2 aminomethyl;each W is Cl, Br, I, F, halogenated alkyl, alkoxy, OH, SH, O-alkyl, S-alkyl, O-alkenyl, O-alkynyl, S-alkenyl, S-alkynyl, —
OC(O)NR4R4, O-acyl, S-acyl, CN, SCN, OCN, NO2, N3, NH2, NH(alkyl), N(alkyl)2, NH-cycloalkyl, NH-acyl, NH═
NH, CONH2, CONH(alkyl), or CON(alkyl)2; andeach R4 is independently H, acyl, or C1-6 alkyl; each Z is O, S, NH, N—
OH, N—
NH2, NH(alkyl), N(alkyl)2, N-cycloalkyl, alkoxy, CN, SCN, OCN, SH, NO2, NH2, N3, NH═
NH, NH(alkyl), N(alkyl)2, CONH2, CONH(alkyl), or CON(alkyl)2;with the caveat that when X is S, then the compound is not 5-(4-amino-imidazo[4,5-d][1,2,3]triazin-7-yl)-2-hydroxymethyl-tetrahydro-thiophen-3-ol or 7-(4-hydroxy-5-hydroxy-methyl-tetrahydro-thiophen-2-yl)-3,7-dihydro-imidazo[4,5-d][1,2,3]triazin-4-one.
-
-
2. A method of treating a host infected with a flavivirus or pestivirus, comprising administering an effective amount of an anti-pestivirus or anti-flavivirus biologically active ribofuranonucleoside of Formula (II):
-
or a pharmacologically acceptable salt or prodrug thereof, wherein; X* is CY3; Y3 is hydrogen, alkyl, bromo, chloro, fluoro, iodo, azido, cyano, alkenyl, alkynyl, —
C(O)O(alkyl), —
C(O)O(lower alkyl), CF3, —
CONH2, —
CONH(alkyl), or —
CON(alkyl)2;R is H, mono-, di-, or triphosphate, a stabilized phosphate, or phosphonate; R1 is H, OH, optionally substituted alkyl, lower alkyl, azido, cyano, optionally substituted alkenyl or alkynyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), —
O(alkynyl), halogen, halogenated alkyl, —
NO2, —
NH2, —
NH(lower alkyl), —
N(lower alkyl)2, —
NH(acyl), —
N(acyl)2, —
C(O)NH2, —
C(O)NH(alkyl), or —
C(O)N(alkyl)2, wherein an optional substitution on alkyl, alkenyl, and/or alkynyl may be one or more halogen, hydroxy, alkoxy or alkylthio groups taken in any combination;each R2 and R3 independently is OH, NH2, F, Cl, Br, I, CN, NO2, C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, N3, optionally substituted alkyl, lower alkyl, optionally substituted alkenyl or alkynyl, halogenated alkyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), an amino acid residue or derivative, a prodrug or leaving group that provides OH in vivo, or an optionally substituted 3-7 membered heterocyclic ring having O, S and/or N independently as a heteroatom taken alone or in combination;each R2′
and R3′
independently is H;
optionally substituted alkyl, alkenyl, or alkynyl;
—
C(O)O(alkyl), —
C(O)O(lower alkyl), —
C(O)O(alkenyl), —
C(O)O(alkynyl), —
C(O)NH2, C(O)NH(alkyl), and —
C(O)N(alkyl)2, —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), halogen, halogenated alkyl and particularly CF3, azido, cyano, NO2, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), NH2, —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), —
NH(acyl), or —
N(acyl)2, and R3 at 3′
-C may also be OH; andBase is selected from the group consisting of; wherein each R′ and
R″
independently is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, halogenated alkyl, OH, CN, N3, carboxy, C1-4alkoxycarbonyl, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfonyl, (C1-4 alkyl)0-2 aminomethyl;each W is Cl, Br, I, F, halogenated alkyl, alkoxy, OH, SH, O-alkyl, S-alkyl, O-alkenyl, O-alkynyl, S-alkenyl, S-alkynyl, —
OC(O)NR4R4, O-acyl, S-acyl, CN, SCN, OCN, NO2, N3, NH2, NH(alkyl), N(alkyl)2, NH-cycloalkyl, NH-acyl, NH═
NH, CONH2, CONH(alkyl), or CON(alkyl)2; andeach R4 is independently H, acyl, or C1-6 alkyl; each Z is O, S, NH, N—
OH, N—
NH2, NH(alkyl), N(alkyl)2, N-cycloalkyl, alkoxy, CN, SCN, OCN, SH, NO2, NH2, N3, NH═
NH, NH(alkyl), N(alkyl)2, CONH2, CONH(alkyl), or CON(alkyl)2.
-
-
3. A method of treating a host infected with a flavivirus or pestivirus, comprising administering an effective amount of an anti-pestivirus or anti-flavivirus biologically active ribofuranonucleoside of Formula (III):
-
or a pharmacologically acceptable salt or prodrug thereof, wherein; each R, R2*, and R3* independently is H, mono-, di-, or triphosphate, a stabilized phosphate, or phosphonate;
optionally substituted alkyl, lower alkyl, optionally substituted alkenyl or alkynyl, acyl, —
C(O)-(alkyl), —
C(O)(lower alkyl), —
C(O)-(alkenyl), —
C(O)-(alkynyl), lipid, phospholipid, carbohydrate, peptide, cholesterol, an amino acid residue or derivative, or other pharmaceutically acceptable leaving group that is capable of providing H or phosphate when administered in vivo;X is O, S[O]n, CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—
O-alkyl, CH—
O-alkenyl, CH—
O-alkynyl, CH—
S-alkyl, CH—
S-alkenyl, CH—
S-alkynyl, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, SCH-halogen, or C-(halogen)2, wherein alkyl, alkenyl or alkynyl optionally may be substituted;n is 0-2; each R2′
independently is H;
optionally substituted alkyl, alkenyl, or alkynyl;
—
C(O)O(alkyl), —
C(O)O(lower alkyl), —
C(O)O(alkenyl), —
C(O)C(alkynyl), —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, —
OH, —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), halogen, halogenated alkyl and particularly CF3, azido, cyano, NO2, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), NH2, —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), —
NH(acyl), or —
N(acyl)2; andBase is selected from the group consisting of; wherein each R′ and
R″
independently is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, halogenated alkyl, OH, CN, N3, carboxy, C1-4alkoxycarbonyl, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfonyl, (C1-4 alkyl)0-2 aminomethyl;each W is Cl, Br, I, F, halogenated alkyl, alkoxy, OH, SH, O-alkyl, S-alkyl, O-alkenyl, O-alkynyl, S-alkenyl, S-alkynyl, —
OC(O)NR4R4, O-acyl, S-acyl, CN, SCN, OCN, NO2, N3, NH2, NH(alkyl), N(alkyl)2, NH-cycloalkyl, NH-acyl, NH═
NH, CONH2, CONH(alkyl), or CON(alkyl)2; andeach R4 is independently H, acyl, or C1-6 alkyl; each Z is O, S, NH, N—
OH, N—
NH2, NH(alkyl), N(alkyl)2, N-cycloalkyl, alkoxy, CN, SCN, OCN, SH, NO2, NH2, N3, NH═
NH, NH(alkyl), N(alkyl)2, CONH2, CONH(alkyl), or CON(alkyl)2.- View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A method of treating a host infected with a flavivirus or pestivirus, comprising administering an effective amount of an anti-pestivirus or anti-flavivirus biologically active ribofuranonucleoside of Formula (IV):
-
or a pharmacologically acceptable salt or prodrug thereof, wherein; each R, R2*, and R3* independently is H, mono-, di-, or triphosphate, a stabilized phosphate, or phosphonate;
optionally substituted alkyl, lower alkyl, optionally substituted alkenyl or alkynyl, acyl, —
C(O)-(alkyl), —
C(O)(lower alkyl), —
C(O)-(alkenyl), —
C(O)-(alkynyl), lipid, phospholipid, carbohydrate, peptide, cholesterol, an amino acid residue or derivative, or other pharmaceutically acceptable leaving group that is capable of providing H or phosphate when administered in vivo;X is O, S[O]n, CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—
O-alkyl, CH—
O-alkenyl, CH—
O-alkynyl, CH—
S-alkyl, CH—
S-alkenyl, CH—
S-alkynyl, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, SCH-halogen, or C-(halogen)2, wherein alkyl, alkenyl or alkynyl optionally may be substituted;n is 0-2; each R3′
independently is H;
optionally substituted alkyl, alkenyl, or alkynyl;
—
C(O)O(alkyl), —
C(O)O(lower alkyl), —
C(O)O(alkenyl), —
C(O)O(alkynyl), —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, —
OH, —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), halogen, halogenated alkyl and particularly CF3, azido, cyano, NO2, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), NH2, —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), —
NH(acyl), or —
N(acyl)2; andBase is selected from the group consisting of; wherein each R′ and
R″
independently is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, halogenated alkyl, OH, CN, N3, carboxy, C1-4alkoxycarbonyl, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfonyl, (C1-4 alkyl)0-2 aminomethyl;each W is Cl, Br, I, F, halogenated alkyl, alkoxy, OH, SH, O-alkyl, S-alkyl, O-alkenyl, O-alkynyl, S-alkenyl, S-alkynyl, —
OC(O)NR4R4, O-acyl, S-acyl, CN, SCN, OCN, NO2, N3, NH2, NH(alkyl), N(alkyl)2, NH-cycloalkyl, NH-acyl, NH═
NH, CONH2, CONH(alkyl), or CON(alkyl)2; andeach R4 is independently H, acyl, or C1-6 alkyl; each Z is O, S, NH, N—
OH, N—
NH2, NH(alkyl), N(alkyl)2, N-cycloalkyl, alkoxy, CN, SCN, OCN, SH, NO2, NH2, N3, NH═
NH, NH(alkyl), N(alkyl)2, CONH2, CONH(alkyl), or CON(alkyl)2.- View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
-
-
35. A compound of the general structure of Formula (I):
-
or a pharmacologically acceptable salt or prodrug thereof, wherein; R is H, mono-, di-, or triphosphate, a stabilized phosphate, or phosphonate; X is O, S[O]n, CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—
O-alkyl, CH—
O-alkenyl, CH—
O-alkynyl, CH—
S-alkyl, CH—
S-alkenyl, CH—
S-alkynyl, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, SCH-halogen, or C-(halogen)2, wherein alkyl, alkenyl or alkynyl may optionally be substituted;n is 0-2; such than when X is CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—
O-alkyl, CH—
O-alkenyl, CH—
O-alkynyl, CH—
S-alkyl, CH—
S-alkenyl, CH—
S-alkynyl, CH-halogen, or C-(halogen)2,then each R1 and R1′
is independently H, OH, optionally substituted alkyl, lower alkyl, azido, cyano, optionally substituted alkenyl or alkynyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), —
O(alkynyl), halogen, halogenated alkyl, —
NO2, —
NH2, —
NH(lower alkyl), —
N(lower alkyl)2, —
NH(acyl), —
N(acyl)2, —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, SCH-halogen, wherein alkyl, alkenyl, and/or alkynyl may optionally be substituted; andsuch that when X is O, S[O]n, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, or SCH-halogen, then each R1 and R1′
is independently H, optionally substituted alkyl, lower alkyl, azido, cyano, optionally substituted alkenyl or alkynyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), halogenated alkyl, —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, —
C(H)═
N—
NH2, C(S)NH2, C(S)NH(alkyl), or C(S)N(alkyl)2, wherein alkyl, alkenyl and/or alkynyl may optionally be substituted;each R2 and R3 independently is OH, NH2, SH, F, Cl, Br, I, CN, NO2, C(O)NH2, —
C(O)NH(alkyl), and —
C(O)N(alkyl)2, N3, optionally substituted alkyl, lower alkyl, optionally substituted alkenyl or alkynyl, halogenated alkyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), —
O(acyl), —
O(alkyl), —
O(alkenyl), —
O(alkynyl), —
OC(O)NH2, NC, C(O)OH, SCN, OCN, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), an amino acid residue or derivative, a prodrug or leaving group that provides OH in vivo, or an optionally substituted 3-7 membered heterocyclic ring having O, S and/or N independently as a heteroatom taken alone or in combination;each R2′
and R3′
independently is H;
optionally substituted alkyl, alkenyl, or alkynyl;
—
C(O)O(alkyl), —
C(O)O(lower alkyl), —
C(O)O(alkenyl), —
C(O)O(alkynyl), —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), halogen, halogenated alkyl and particularly CF3, azido, cyano, NO2, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), NH2, —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), —
NH(acyl), or —
N(acyl)2, and R3 at 3′
-C may also be OH; andBase is selected from the group consisting of; wherein each R′ and
R″
independently is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, halogenated alkyl, OH, CN, N3, carboxy, C1-4alkoxycarbonyl, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfonyl, (C1-4 alkyl)0-2 aminomethyl;each W is Cl, Br, I, F, halogenated alkyl, alkoxy, OH, SH, O-alkyl, S-alkyl, O-alkenyl, O-alkynyl, S-alkenyl, S-alkynyl, —
OC(O)NR4R4, O-acyl, S-acyl, CN, SCN, OCN, NO2, N3, NH2, NH(alkyl), N(alkyl)2, NH-cycloalkyl, NH-acyl, NH═
NH, CONH2, CONH(alkyl), or CON(alkyl)2; andeach R4 is independently H, acyl, or C1-6 alkyl; each Z is O, S, NH, N—
OH, N—
NH2, NH(alkyl), N(alkyl)2, N-cycloalkyl, alkoxy, CN, SCN, OCN, SH, NO2, NH2, N3, NH═
NH, NH(alkyl), N(alkyl)2, CONH2, CONH(alkyl), or CON(alkyl)2;with the caveat that when X is S, then the compound is not 5-(4-amino-imidazo[4,5-d][1,2,3]triazin-7-yl)-2-hydroxymethyl-tetrahydro-thiophen-3-ol or 7-(4-hydroxy-5-hydroxy-methyl-tetrahydro-thiophen-2-yl)-3,7-dihydro-imidazo[4,5-d][1,2,3]triazin-4-one.
-
-
36. A compound of the general structure of Formula (II):
-
or a pharmacologically acceptable salt or prodrug thereof, wherein; X* is CY3; Y3 is hydrogen, alkyl, bromo, chloro, fluoro, iodo, azido, cyano, alkenyl, alkynyl, —
C(O)O(alkyl), —
C(O)O(lower alkyl), CF3, —
CONH2, —
CONH(alkyl), or —
CON(alkyl)2;R is H, mono-, di-, or triphosphate, a stabilized phosphate, or phosphonate; R1 is H, OH, optionally substituted alkyl, lower alkyl, azido, cyano, optionally substituted alkenyl or alkynyl, —
C(O)O-(alkyl), c(O)O(lower alkyl), —
C(O)O-(alkenyl), —
(O)O-(alkynyl), —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), —
O(alkynyl), halogen, halogenated alkyl, —
NO2, —
NH2, —
NH(lower alkyl), —
N(lower alkyl), —
NH(acyl), —
N(acyl)2, —
C(O)NH2, —
C(O)NH(alkyl), or —
C(O)N(alkyl)2, wherein an optional substitution on alkyl, alkenyl, and/or alkynyl may be one or more halogen, hydroxy, alkoxy or alkylthio groups taken in any combination;each R2 and R3 independently is OH, NH2, F, Cl, Br, I, CN, NO2, —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, N3, optionally substituted alkyl, lower alkyl, optionally substituted alkenyl or alkynyl, halogenated alkyl, —
C(O)O-(alkyl), —
C(O)O(lower alkyl), —
C(O)O-(alkenyl), —
C(O)O-(alkynyl), an amino acid residue or derivative, a prodrug or leaving group that provides OH in vivo, or an optionally substituted 3-7 membered heterocyclic ring having O, S and/or N independently as a heteroatom taken alone or in combination;each R2′
and R3′
independently is H;
optionally substituted alkyl, alkenyl, or alkynyl;
—
C(O)O(alkyl), —
C(O)O(lower alkyl), —
C(O)O(alkenyl), —
C(O)O(alkynyl), —
C(O)NH2, —
C(O)NH(alkyl), and —
C(O)N(alkyl)2, —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), halogen, halogenated alkyl and particularly CF3, azido, cyano, NO2, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), NH2, —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), —
NH(acyl), or —
N(acyl)2, and R3 at 3′
-C may also be OH; andBase is selected from the group consisting of; wherein each R′ and
R″
independently is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, halogenated alkyl, OH, CN, N3, carboxy, C1-4alkoxycarbonyl, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfonyl, (C1-4 alkyl)0-2 aminomethyl;each W is Cl, Br, I, F, halogenated alkyl, alkoxy, OH, SH, O-alkyl, S-alkyl, O-alkenyl, O-alkynyl, S-alkenyl, S-alkynyl, —
OC(O)NR4R4, O-acyl, S-acyl, CN, SCN, OCN, NO2, N3, NH2, NH(alkyl), N(alkyl)2, NH-cycloalkyl, NH-acyl, NH═
NH, CONH2, CONH(alkyl), or CON(alkyl)2; andeach R4 is independently H, acyl, or C1-6 alkyl; each Z is O, S, NH, N—
OH, N—
NH2, NH(alkyl), N(alkyl)2, N-cycloalkyl, alkoxy, CN, SCN, OCN, SH, NO2, NH2, N3, NH═
NH, NH(alkyl), N(alkyl)2, CONH2, CONH(alkyl), or CON(alkyl)2.
-
-
37. A compound of the general structure of Formula (III):
-
or a pharmacologically acceptable salt or prodrug thereof, wherein; each R, R2*, and R3* independently is H, mono-, di-, or triphosphate, a stabilized phosphate, or phosphonate;
optionally substituted alkyl, lower alkyl, optionally substituted alkenyl or alkynyl, acyl, —
C(O)-(alkyl), —
C(O)(lower alkyl), —
C(O)-(alkenyl), —
C(O)-(alkynyl), lipid, phospholipid, carbohydrate, peptide, cholesterol, an amino acid residue or derivative, or other pharmaceutically acceptable leaving group that is capable of providing H or phosphate when administered in vivo;X is O, S[O]n, CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—
O-alkyl, CH—
O-alkenyl, CH—
O-alkynyl, CH—
S-alkyl, CH—
S-alkenyl, CH—
S-alkynyl, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, SCH-halogen, or C-(halogen)2, wherein alkyl, alkenyl or alkynyl optionally may be substituted;n is 0-2; each R2′
independently is H;
optionally substituted alkyl, alkenyl, or alkynyl;
—
C(O)O(alkyl), —
C(O)O(lower alkyl), —
C(O)O(alkenyl), —
C(O)O(alkynyl), —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, —
OH, —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), halogen, halogenated alkyl and particularly CF3, azido, cyano, NO2, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), NH2, —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), —
NH(acyl), or —
N(acyl)2; andBase is selected from the group consisting of; wherein each R′ and
R″
independently is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, halogenated alkyl, OH, CN, N3, carboxy, C1-4alkoxycarbonyl, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfonyl, (C1-4 alkyl)0-2 aminomethyl;each W is Cl, Br, I, F, halogenated alkyl, alkoxy, OH, SH, O-alkyl, S-alkyl, O-alkenyl, O-alkynyl, S-alkenyl, S-alkynyl, —
OC(O)NR4R4, O-acyl, S-acyl, CN, SCN, OCN, NO2, N3, NH2, NH(alkyl), N(alkyl)2, NH-cycloalkyl, NH-acyl, NH═
NH, CONH2, CONH(alkyl), or CON(alkyl); andeach R4 is independently H, acyl, or C1-6 alkyl; each Z is O, S, NH, N—
OH, N—
NH2, NH(alkyl), N(alkyl)2, N-cycloalkyl, alkoxy, CN, SCN, OCN, SH, NO2, NH2, N3, NH═
NH, NH(alkyl), N(alkyl)2, CONH2, CONH(alkyl), or CON(alkyl)2.- View Dependent Claims (38, 39, 40, 41, 42, 43, 44, 45, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)
-
-
46. A compound of the general structure of Formula (IV):
-
or a pharmacologically acceptable salt or prodrug thereof, wherein; each R, R2*, and R3* independently is H, mono-, di-, or triphosphate, a stabilized phosphate, or phosphonate;
optionally substituted alkyl, lower alkyl, optionally substituted alkenyl or alkynyl, acyl, —
C(O)-(alkyl), —
C(O)(lower alkyl), —
C(O)-(alkenyl), —
C(O)-(alkynyl), lipid, phospholipid, carbohydrate, peptide, cholesterol, an amino acid residue or derivative, or other pharmaceutically acceptable leaving group that is capable of providing H or phosphate when administered in vivo;X is O, S[O]n, CH2, CHOH, CH-alkyl, CH-alkenyl, CH-alkynyl, C-dialkyl, CH—
O-alkyl, CH—
C-alkenyl, CH—
O-alkynyl, CH—
S-alkyl, CH—
S-alkenyl, CH—
S-alkynyl, NH, N-alkyl, N-alkenyl, N-alkynyl, S(O)N-alkyl, S(O)N-alkenyl, S(O)N-alkynyl, SCH-halogen, or C-(halogen)2, wherein alkyl, alkenyl or alkynyl optionally may be substituted;n is 0-2; each R3′
independently is H;
optionally substituted alkyl, alkenyl, or alkynyl;
—
C(O)O(alkyl), —
C(O)O(lower alkyl), —
C(O)O(alkenyl), —
C(O)O(alkynyl), —
C(O)NH2, —
C(O)NH(alkyl), —
C(O)N(alkyl)2, —
OH, —
O(acyl), —
O(lower acyl), —
O(alkyl), —
O(lower alkyl), —
O(alkenyl), halogen, halogenated alkyl and particularly CF3, azido, cyano, NO2, —
S(alkyl), —
S(alkenyl), —
S(alkynyl), NH2, —
NH(alkyl), —
N(alkyl)2, —
NH(alkenyl), —
NH(alkynyl), —
NH(acyl), or —
N(acyl)2; andBase is selected from the group consisting of; wherein each R′ and
R″
independently is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, halogenated alkyl, OH, CN, N3, carboxy, C1-4alkoxycarbonyl, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfonyl, (C1-4 alkyl)0-2 aminomethyl;each W is Cl, Br, I, F, halogenated alkyl, alkoxy, OH, SH, O-alkyl, S-alkyl, O-alkenyl, O-alkynyl, S-alkenyl, S-alkynyl, —
OC(O)NR4R4, O-acyl, S-acyl, CN, SCN, OCN, NO2, N3, NH2, NH(alkyl), N(alkyl)2, NH-cycloalkyl, NH-acyl, NH═
NH, CONH2, CONH(alkyl), or CON(alkyl)2; andeach R4 is independently H, acyl, or C1-6 alkyl; each Z is O, S, NH, N—
OH, N—
NH2, NH(alkyl), N(alkyl)2, N-cycloalkyl, alkoxy, CN, SCN, OCN, SH, NO2, NH2, N3, NH═
NH, NH(alkyl), N(alkyl)2, CONH2, CONH(alkyl), or CON(alkyl)2.- View Dependent Claims (47, 48, 49, 50, 51, 52, 53, 54)
-
Specification